BIOCONPharmaceuticals
Biocon Ltd — Cash Flow Statement
₹360.90
-2.52%
Biocon Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.72K Cr | 1.02K Cr | 126.20 Cr | -748.20 Cr | — |
| Repayment Of Debt | -9.77K Cr | -2.77K Cr | -28.10 Cr | -1.09K Cr | — |
| Issuance Of Debt | 9.66K Cr | 1.37K Cr | 10.94K Cr | 1.07K Cr | — |
| Issuance Of Capital Stock | 10.40 Cr | 30.70 Cr | 1.27K Cr | 42.80 Cr | — |
| Capital Expenditure | -2.34K Cr | -1.93K Cr | -1.73K Cr | -1.92K Cr | — |
| End Cash Position | 2.92K Cr | 919.50 Cr | 1.29K Cr | 653.70 Cr | — |
| Beginning Cash Position | 919.50 Cr | 1.30K Cr | 653.70 Cr | 897.00 Cr | — |
| Effect Of Exchange Rate Changes | 31.20 Cr | 2.90 Cr | 21.70 Cr | 3.30 Cr | — |
| Changes In Cash | 1.97K Cr | -383.30 Cr | 619.40 Cr | -280.40 Cr | — |
| Financing Cash Flow | -1.85K Cr | -2.33K Cr | 13.05K Cr | 242.10 Cr | — |
| Net Other Financing Charges | -1.58K Cr | — | — | — | — |
| Interest Paid Cff | -634.20 Cr | -847.40 Cr | -485.60 Cr | -109.60 Cr | — |
| Cash Dividends Paid | -82.90 Cr | -203.00 Cr | -71.80 Cr | — | — |
| Net Common Stock Issuance | 10.40 Cr | 30.70 Cr | 1.20K Cr | 42.50 Cr | — |
| Common Stock Issuance | 10.40 Cr | 30.70 Cr | 1.27K Cr | 42.80 Cr | — |
| Net Issuance Payments Of Debt | 572.90 Cr | -1.27K Cr | 12.42K Cr | 321.30 Cr | — |
| Net Short Term Debt Issuance | 684.60 Cr | 124.80 Cr | 1.50K Cr | 346.10 Cr | — |
| Net Long Term Debt Issuance | -111.70 Cr | -1.40K Cr | 10.91K Cr | -24.80 Cr | — |
| Long Term Debt Payments | -9.77K Cr | -2.77K Cr | -28.10 Cr | -1.09K Cr | — |
| Long Term Debt Issuance | 9.66K Cr | 1.37K Cr | 10.94K Cr | 1.07K Cr | — |
| Investing Cash Flow | -234.10 Cr | -1.00K Cr | -14.28K Cr | -1.70K Cr | — |
| Interest Received Cfi | 114.40 Cr | 144.60 Cr | 123.30 Cr | 59.60 Cr | — |
| Dividends Received Cfi | 2.80 Cr | 0.00 | — | — | — |
| Net Investment Purchase And Sale | 166.50 Cr | 1.31K Cr | -464.80 Cr | 231.40 Cr | — |
| Sale Of Investment | 10.41K Cr | 6.65K Cr | 18.25K Cr | 8.03K Cr | — |
| Purchase Of Investment | -10.24K Cr | -5.33K Cr | -18.71K Cr | -7.79K Cr | — |
| Net Business Purchase And Sale | 1.83K Cr | -553.20 Cr | -12.22K Cr | 0.00 | — |
| Sale Of Business | 1.83K Cr | 0.00 | 3.45K Cr | 0.00 | — |
| Purchase Of Business | 0.00 | -553.20 Cr | -15.66K Cr | 0.00 | — |
| Net Intangibles Purchase And Sale | -206.70 Cr | -251.10 Cr | -130.30 Cr | -227.00 Cr | — |
| Purchase Of Intangibles | -206.70 Cr | -251.10 Cr | -130.30 Cr | -227.00 Cr | — |
| Net PPE Purchase And Sale | -2.14K Cr | -1.66K Cr | -1.59K Cr | -1.70K Cr | — |
| Sale Of PPE | 0.30 Cr | 23.30 Cr | 3.10 Cr | 2.10 Cr | — |
| Purchase Of PPE | -2.14K Cr | -1.68K Cr | -1.60K Cr | -1.70K Cr | — |
| Operating Cash Flow | 4.06K Cr | 2.95K Cr | 1.85K Cr | 1.18K Cr | — |
| Taxes Refund Paid | -459.60 Cr | -292.30 Cr | -228.60 Cr | -262.00 Cr | — |
| Change In Working Capital | 923.00 Cr | -635.20 Cr | -501.00 Cr | -789.50 Cr | — |
| Change In Other Current Assets | -205.70 Cr | -267.90 Cr | 758.20 Cr | -63.70 Cr | — |
| Change In Payable | 580.80 Cr | 2.94K Cr | -3.74K Cr | 161.80 Cr | — |
| Change In Inventory | -0.30 Cr | -886.40 Cr | 886.20 Cr | -414.00 Cr | — |
| Change In Receivables | 548.20 Cr | -2.42K Cr | 1.59K Cr | -473.60 Cr | — |
| Other Non Cash Items | -130.50 Cr | 1.42K Cr | 356.40 Cr | 77.10 Cr | — |
| Stock Based Compensation | 137.00 Cr | 100.60 Cr | 137.60 Cr | 125.70 Cr | — |
| Provisionand Write Offof Assets | 26.00 Cr | -18.20 Cr | 5.40 Cr | 24.00 Cr | — |
| Deferred Tax | 457.20 Cr | 227.40 Cr | 254.10 Cr | 211.50 Cr | — |
| Depreciation And Amortization | 1.69K Cr | 1.57K Cr | 1.11K Cr | 814.20 Cr | — |
| Amortization Cash Flow | 685.90 Cr | 629.50 Cr | 291.40 Cr | 131.00 Cr | — |
| Depreciation | 1.00K Cr | 939.30 Cr | 821.70 Cr | 683.20 Cr | — |
| Gain Loss On Investment Securities | 38.70 Cr | -170.10 Cr | -41.60 Cr | 15.30 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -57.60 Cr | -105.40 Cr | 97.10 Cr | 8.60 Cr | — |
| Gain Loss On Sale Of PPE | 7.60 Cr | 1.20 Cr | 5.20 Cr | 2.30 Cr | — |
| Gain Loss On Sale Of Business | 0.00 | -530.70 Cr | -156.20 Cr | -29.90 Cr | — |
| Net Income From Continuing Operations | 1.43K Cr | 1.30K Cr | 643.00 Cr | 771.60 Cr | — |
| Repurchase Of Capital Stock | — | 0.00 | -64.70 Cr | -0.30 Cr | -9.30 Cr |
| Common Stock Dividend Paid | — | -203.00 Cr | -71.80 Cr | 0.00 | — |
| Common Stock Payments | — | 0.00 | -64.70 Cr | -0.30 Cr | -9.30 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | — | 33.80 Cr | -33.80 Cr |
| Net Other Investing Changes | — | — | — | — | -101.80 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Biocon Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.